Protara Therapeutics, Inc.
TARA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001359931
No open-market purchases or sales by Protara Therapeutics, Inc. insiders were filed in the last 90 days; 119 institutions reported holding it in 13F filings for Q2 2026, worth $176.0M in total; no superinvestor holds it.
Q2 2025 vs. Q1 2025
How the institutions holding Protara Therapeutics, Inc. changed between Q1 2025 and Q2 2025.
All holders in Q2 2025All holders in Q1 2025
| Measure | Q1 2025 | Q2 2025 | Change |
|---|---|---|---|
| Holders | 59 | 76 | +17 |
| Shares | 28.8M | 29.7M | +955.0K (+3.3%) |
| Value | $123.8M | $90.1M | −$33.7M (−27.2%) |
New holders (25)
Institutions that held Protara Therapeutics, Inc. at the end of Q2 2025 but not at the end of Q1 2025.
Sold out (8)
Institutions that held Protara Therapeutics, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.
| Institution | Shares, Q1 2025 | Value, Q1 2025 |
|---|---|---|
| Sio Capital Management, LLC | 1,514,300 | $6.45M |
| Driehaus Capital Management LLC | 272,342 | $1.16M |
| Omers Administration Corp | 75,100 | $319.9K |
| Qube Research & Technologies Ltd | 61,917 | $263.8K |
| Jain Global LLC | 19,212 | $81.8K |
| Balyasny Asset Management LLC | 18,710 | $79.7K |
| Quantessence Capital LLC | 10,188 | $43.4K |
| Commonwealth Equity Services, LLC | 10,000 | $43.0K |